Medindia

X

Vical to Present at Upcoming Investor Conferences

Tuesday, November 4, 2008 General News J E 4
Advertisement
NEW YORK, Nov. 4 The Vical Incorporated (Nasdaq: VICL) presentation at the Rodman & Renshaw Annual Global Investor Conference at 4:05 p.m. Eastern Time on Tuesday, November 11, will be available by live and archived webcast through the Events page at www.vical.com. Vical's presentation at the Lazard Capital Markets 5th Annual Healthcare Conference on Tuesday, November 18, will not be webcast.



About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.



This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.



Contact: Alan R. Engbring (858) 646-1127 Website: www.vical.com

SOURCE Vical Incorporated
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
CorVel Announces Second Quarter Revenues and Earni...
S
Neurobiological Technologies Sets Date for First Q...